Matthew Alder, MD, PhD
- Attending Physician, Pediatric Intensive Care Unit
- Assistant Professor, UC Department of Pediatrics
- matthew.alder@cchmc.org
- Board Certified
About
Biography
My interest in pediatric medicine began at a young age. I was quite ill as a child and became inspired by the physicians who cared for me.
During college, I realized I also enjoyed research. So, I decided to pursue a career that would combine research and patient care. I completed a fellowship in critical care and a PhD in microbiology and immunology.
Today, I work in the Pediatric Intensive Care Unit, where I continuously care for children who struggle to overcome sepsis. My research, which draws on my training in neutrophil biology, neutrophil heterogeneity and immunology in the critically ill, aims to understand why some kids quickly recover from sepsis while others do not.
I’ve received research funding from a variety of sources. This funding includes a K08 Mentored Clinical Scientist Development Award from the National Institute of General Medical Sciences and a Procter Scholar Award from Cincinnati Children’s.
BA: Mandarin Chinese, University of Utah, Salt Lake City, UT, 2002.
MD, PhD: Microbiology and Immunology, University of Alabama, Birmingham, AL, 2009.
Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2012.
Fellowship: Critical Care, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2015.
Interests
Pediatric critical care
Services and Specialties
Pediatric Intensive Care Unit PICU
Interests
Immunology; sepsis
Research Areas
Critical Care
Additional Languages
MandarinPublications
Olfactomedin-4-Positive Neutrophils in Neonates: Link to Systemic Inflammation and Bronchopulmonary Dysplasia. Neonatology. 2022; 1-9.
Biomarkers estimating baseline mortality risk for neonatal sepsis: nPERSEVERE: neonate-specific sepsis biomarker risk model. Pediatric Research. 2022.
Integrated PERSEVERE and endothelial biomarker risk model predicts death and persistent MODS in pediatric septic shock: a secondary analysis of a prospective observational study. Critical Care. 2022; 26.
Olfactomedin 4 as a novel loop of Henle-specific acute kidney injury biomarker. Physiological Reports. 2022; 10.
Candidate Biomarkers for Sepsis-Associated Acute Kidney Injury Mechanistic Studies. Shock. 2022; 57:687-693.
A neutrophil subset defined by intracellular olfactomedin 4 is associated with mortality in sepsis. American Journal of Physiology - Lung Cellular and Molecular Physiology. 2021; 320:L892-L902.
Olfactomedin 4-Positive Neutrophils Are Upregulated after Hemorrhagic Shock. American Journal of Respiratory Cell and Molecular Biology. 2021; 64:216-223.
Longitudinal characterization of olfactomedin-4 expressing neutrophils in pediatric patients undergoing bone marrow transplantation. PLoS ONE. 2020; 15.
Pre-operative neutrophil-lymphocyte ratio predicts low cardiac output in children after cardiac surgery. Cardiology in the Young. 2020; 30:521-525.
Juvenile OLFM4-null mice are protected from sepsis. American Journal of Physiology - Renal Physiology. 2020; 318:F809-F816.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2022 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey